HRMY Harmony Biosciences 2026 stock outlook: WAKIX narcolepsy revenue tracking above $1 billion, pipeline expansion, single-product concentration, orexin competition, generic timing, peers, and US tax angles for investors.
RARE (Ultragenyx Pharmaceutical) stock outlook for 2026: a rare-disease and gene therapy biotech down 57% in a year, with Crysvita cash flow, binary trial readouts, dilution risk and a US-investor playbook for sizing and taxes.
KRYS Krystal Biotech stock outlook 2026: VYJUVEK profitability, single-product risk, inhaled and eye pipeline, competitors, plus US tax and FX angles.
PTCT (PTC Therapeutics) 2026 stock outlook. A hard look at the rare-disease commercial franchise, the Evrysdi royalty stream, Novartis Huntington's milestone cash, the gene-therapy and splicing pipeline, the Translarna revenue hole, and the reimbursement and clinical risks that drive this biopharma.
BioMarin Pharmaceutical (BMRN) 2026 stock analysis: orphan-drug moat, Voxzogo achondroplasia growth and competition, the Amicus acquisition, Roctavian's commercial miss, pricing risk, and the quarterly metrics that matter.
ADMA Biologics stock outlook for 2026, covering the ASCENIV and BIVIGAM specialty immunoglobulin franchise, vertically integrated plasma collection, pediatric label expansion, competitive pressure from Grifols and CSL, and the concentration and regulatory risks investors should weigh before buying ADMA shares.
Genexine (095700) stock outlook for 2026. A deep look at the hyFc long-acting protein platform, the IL-7 immuno-oncology and rare-disease pipeline, the NeoImmuneTech link, R&D losses and dilution risk, and how it stacks up against Hanmi and Alteogen.
INSM (Insmed) stock outlook for 2026. A qualitative deep dive into the Arikayce revenue base for NTM lung disease, the brensocatib bronchiectasis catalyst, the TPIP pulmonary hypertension pipeline, and the commercialization-transition and cash-burn risks that define this late-stage biotech.
Sarepta Therapeutics (SRPT) Stock Outlook 2026 covering the ELEVIDYS DMD gene therapy, the 2025 patient-death safety events and FDA scrutiny that crushed the stock, the exon-skipping revenue base, RNA and gene-therapy pipeline, binary biotech risk, peer comparison and what global investors should weigh on tax, currency and dilution.
BEAM Beam Therapeutics stock outlook 2026. Base editing technology moat, BEAM-101 sickle cell and beta-thalassemia pipeline, CRSP and NTLA competition, clinical binary risk, cash runway, and a practical positioning framework for investors.
A qualitative deep dive into the 2026 outlook for GC Biopharma (KRX: 006280), Korea's plasma-products leader. We cover the FDA approval and US market push of its immunoglobulin ALYGLO as the core growth catalyst, the vaccine, rare-disease (Hunterase), prescription and consumer-health segments, plasma cost and R&D pressures, earnings volatility and valuation risk, plus practical framing for international investors.
CRSP CRISPR Therapeutics 2026. Casgevy CRISPR therapy, BEAM NTLA BLUE competition, CAR-T pipeline, and commercialization scenarios for investors.